Company news

Vistagen Therapeutics, Inc. news in 2020

Vistagen Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.

View company

VistaGen Announces Publication in CNS Spectrums Detailing Proposed Mechanism of Action of Its Investigational Neuroactive Nasal Sprays for Anxiety and Depression Disorders

December 29, 2020

VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering

December 21, 2020

VistaGen Therapeutics Announces Pricing of Underwritten Public Offering

December 17, 2020

VistaGen Therapeutics Announces Proposed Underwritten Public Offering

December 16, 2020

VistaGen Announces Korean Intellectual Property Office Decision to Grant PH10 Patent for Treatment of Depression

December 9, 2020

VistaGen Therapeutics Reports Fiscal 2021 Second Quarter Financial Results and Provides Highlights on its CNS Pipeline and Business Progress

November 11, 2020

VistaGen Reports Positive New Data from Second Preclinical Study of AV-101 in Combination with Probenecid

September 2, 2020

VistaGen Therapeutics Reports Fiscal 2021 First Quarter Financial Results and Highlights CNS Pipeline and Business Progress

August 12, 2020

VistaGen Therapeutics Announces Exercise and Closing of Underwriters' Over-allotment Option in Underwritten Public Offering

August 9, 2020

VistaGen Therapeutics Announces Closing of $12.5 Million Underwritten Public Offering

August 4, 2020

VistaGen Therapeutics Announces Receipt of $5 Million Non-Dilutive Upfront License Payment from EverInsight Therapeutics for PH94B Strategic Collaboration

August 3, 2020

VistaGen Therapeutics Announces Pricing of $12.5 Million Underwritten Public Offering of Common Stock

August 1, 2020

VistaGen Therapeutics Announces Proposed Public Offering of Common Stock

July 30, 2020

VistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94B for Acute Treatment of Anxiety in Patients with Social Anxiety Disorder

July 22, 2020

VistaGen Therapeutics Reports Fiscal Year 2020 Results and Provides CNS Pipeline Update

June 28, 2020

VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia

June 24, 2020

VistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS Conditions

May 26, 2020

VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP)

May 17, 2020

VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19

April 27, 2020

VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million

March 24, 2020

VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder

February 19, 2020

VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview

February 12, 2020

VistaGen Therapeutics Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration Effects

February 10, 2020

VistaGen Therapeutics Receives FDA Clearance of IND for Phase 2 Clinical Study of AV-101 as a Potential Treatment of Dyskinesia in Parkinson's Disease Patients

January 29, 2020

Decks in 2020